SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month High – Should You Buy?

Posted by Francis Steltz on Jul 3rd, 2026

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as $15.88 and last traded at $14.76, with a volume of 21504395 shares traded. The stock had previously closed at $15.45.

Analyst Ratings Changes

Several brokerages have recently issued reports on SLS. Maxim Group upped their target price on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, SELLAS Life Sciences Group currently has an average rating of “Hold” and a consensus target price of $10.00.

Check Out Our Latest Analysis on SELLAS Life Sciences Group

SELLAS Life Sciences Group Stock Performance

The company has a market cap of $2.95 billion, a PE ratio of -65.13 and a beta of 2.41. The stock’s 50-day simple moving average is $7.91 and its 200 day simple moving average is $5.54.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of institutional investors and hedge funds have recently bought and sold shares of SLS. Anson Funds Management LP boosted its position in SELLAS Life Sciences Group by 2,093.8% in the 3rd quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after buying an additional 5,757,938 shares during the last quarter. Marshall Wace LLP increased its position in shares of SELLAS Life Sciences Group by 23,550.0% during the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock worth $5,947,000 after acquiring an additional 2,704,007 shares during the last quarter. Geode Capital Management LLC increased its position in shares of SELLAS Life Sciences Group by 168.2% during the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock worth $4,819,000 after acquiring an additional 1,379,988 shares during the last quarter. Millennium Management LLC lifted its stake in shares of SELLAS Life Sciences Group by 341.0% in the fourth quarter. Millennium Management LLC now owns 1,387,849 shares of the company’s stock worth $5,232,000 after acquiring an additional 1,073,147 shares in the last quarter. Finally, State Street Corp boosted its holdings in SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company’s stock valued at $8,249,000 after purchasing an additional 827,257 shares during the last quarter. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.